Abstract
Background
Dermatologic manifestations of inflammatory bowel disease (IBD) are common, and certain IBD medications increase the risk of skin cancer.
Aims
To define the rates of care and factors associated with dermatologic utilization with a focus on skin cancer screening.
Methods
We utilized a prospective, natural history IBD research registry to evaluate all outpatient healthcare encounters from 2010 to 2016. Gastrointestinal, dermatologic and primary care visits per individual were identified. We calculated the proportion of patients obtaining care, categorized primary indications for dermatologic visits, determined the incidence of melanoma and non-melanoma skin cancers, and used logistic regression to determine factors associated with dermatology utilization.
Results
Of the 2127 IBD patients included, 452 (21.3%) utilized dermatology over the study period, and 55 (2.6%) had a total body skin examination at least once. The 452 patients incurred 1633 dermatology clinic visits, 278 dermatologic procedures, and 1108 dermatology telephone encounters. The most frequent indication was contact dermatitis or dermatitis. Factors associated with dermatology use were family history of skin cancer, employment, systemic steroids, longer disease duration, emergency room use, and the number of IBD-related clinic visits. Between 8.3 and 11% of IBD patients recommended for skin cancer screening visited dermatology each year, and the resulting incidence of non-melanoma skin cancer was 35.4/10,000 [95% CI 23.3–51.5] and melanoma was 6.56/10,000 [95% CI 2.1–15.3].
Conclusions
Less than one in ten IBD patients obtain dermatologic care. Given the increased risk of skin cancers among IBD patients, an emphasis on education, prevention, and screening merits attention.
Similar content being viewed by others
References
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;19:2066–2078.
Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;24:2333–2349.
Hagen JW, Swoger JM, Grandinetti LM. Cutaneous manifestations of crohn disease. Dermatol Clin. 2015;33:417–431.
Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–254.
Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;6:13.
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–227.
Weizman A, Huang B, Berel D, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20:525–533.
Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;5:10–22.
Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480–1487.
Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:e1.
Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–218.
Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:e1.
Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–1904.
McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2014;23:267–271.
Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258.
Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–186.
Abbas AM, Almukhtar RM, Loftus EV, Lichtenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014;109:1781–1793.
Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152:164–172.
Clowry J, Sheridan J, Healy R, et al. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. J Eur Acad Dermatol Venereol. 2017. https://doi.org/10.1111/jdv.14105.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–274.
Saraiya M, Hall HI, Thompson T, et al. Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys. Prev Med. 2004;39:308–314.
Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL. Prevalence and correlates of skin cancer screening among middle-aged and older white adults in the United States. Am J Med. 2010;123:439–445.
Anderson AJ, Click B, Ramos-Rivers C, et al. Development of an inflammatory bowel disease research registry derived from observational electronic health record data for comprehensive clinical phenotyping. Dig Dis Sci. 2016;61:3236–3245.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. The Lancet. 1980;8:514.
Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;1:353–356.
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.
Crohn’s and Colitis Foundation Professional Education Committee Sub Group: CCFA Health Maintenance Checklist for Adult IBD Patients 2017.
Pandey N, Herrera HH, Johnson CM, MacCarthy AA, Copeland LA. Preventative care for patients with inflammatory bowel disease in the Veterans Health Administration. Medicine. 2016;95:e4012.
Long MD, Porter CQ, Sandler RS, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:549–553.
Goldberg MS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001–2005. J Am Acad Dermatol. 2007;57:60–66.
Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513–519.
Robbins HA, Clarke CA, Arron ST, et al. Melanoma Risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135:2657–2665.
Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol. 1999;40:697–701.
Ali FR, Samarasinghe V, Russell SA, Lear JT. Increasing capacity for skin surveillance in a transplant review clinic. Transplantation. 2014;97:e48–e50.
Lloyd A, Klintmalm G, Qin H, Menter A. Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transplant. 2015;29:110–117.
Williams NC, Tong A, Howard K, Chapman JR, Craig JC, Wong G. Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer. Nephrology (Carlton). 2012;17:300–306.
Wisgerhof HC, van der Geest LG, de Fijter JW, et al. Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center. Cancer Epidemiol. 2011;35:105–111.
Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–1876.
Scotto J, Kopf AW, Urbach F. Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer. 1974;34:1333–1338.
Cheng MY, Moreau JF, McGuire ST, Ho J, Ferris LK. Melanoma depth in patients with an established dermatologist. J Am Acad Dermatol. 2014;70:841–846.
Kirsner RS, Muhkerjee S, Federman DG. Skin cancer screening in primary care: prevalence and barriers. J Am Acad Dermatol. 1999;41:564–566.
Oliveria SA, Christos PJ, Marghoob AA, Halpern AC. Skin cancer screening and prevention in the primary care setting: national ambulatory medical care survey 1997. J Gen Intern Med. 2001;16:297–301.
Acknowledgment
We would like to acknowledge the faculty, staff, and most importantly the generosity of our patients who continue to make this research feasible.
Author’s contribution
Alyce Anderson, BS contributed to drafting of manuscript, data organization, statistical analysis, table and figure creation, manuscript revisions, and critical review of the manuscript. Laura Ferris, MD, PhD contributed to data review, advisor to primary author, project supervision, and critical review of the manuscript. Benjamin Click, MD contributed to drafting of manuscript, data collection, and critical review of the manuscript. Claudia Ramos-Rivers, MD contributed to data collection and organization, and critical review of the manuscript. Ioannis E. Koutroubakis, MD, PhD was involved in critical review of the manuscript, collection of data. Jana G. Hashash, MD helped in critical review of the manuscript, collection of data. Michael Dunn, MD contributed to critical review of the manuscript and collection of data. Arthur Barrie, MD, PhD was involved in critical review of the manuscript and collection of data. Marc Schwartz, MD helped in critical review of the manuscript and collection of data. Miguel Regueiro, MD contributed to critical review of the manuscript and collection of data. David Binion, MD helped in critical review of the manuscript, collection of data, and project supervision and was advisor to primary author. All authors read and approved the final manuscript.
Funding
Alyce Anderson is supported by an NIH training Grant (TL1TR001858, PI: Kapoor). David G. Binion reports support from Grant W81XWH-11-2-0133 from the U.S. Army Medical Research and Materiel Command. Laura K. Ferris is supported by a National Cancer Institute Grant (5P50CA121973-08). Research reported in this publication was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR001858. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Alyce Anderson, Laura K. Ferris, Benjamin Click, Claudia Ramos-Rivers, Ioannis E. Koutroubakis, Jana G. Hashash, Michael Dunn, Arthur Barrie, Marc Schwartz, Miguel Regueiro, and David G. Binion declare they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Anderson, A., Ferris, L.K., Click, B. et al. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63, 2729–2739 (2018). https://doi.org/10.1007/s10620-018-5056-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5056-x